The American company COVAXX, which develops a synthetic peptide vaccine to protect against coronavirus infection, has announced a global partnership with Maersk, one of the world’s largest shipping transport and supply companies.
The agreement provides for cooperation on all procurement and transportation issues required for the worldwide delivery of the UB-612 vaccine when it is approved by regulatory authorities. The financial aspects of the agreement were not disclosed.
The vaccine being developed by COVAXX activates class T and B lymphocytes, which play an important role in human immune defense. The company is currently conducting Phase I clinical trials in Taiwan and has an agreement with the University of Nebraska Medical Center to conduct a Phase II clinical trial in the United States. The company also announced its readiness to deliver over 100 million doses of vaccine by early 2021 and a billion doses by the end of this year.
Under the agreement, COVAXX and Maersk are committed to providing management at all stages of vaccine delivery, including packaging and shipping by air and sea, ground transportation, warehousing and distribution to healthcare facilities. In this case, all requirements of the vaccine developers for storage and temperature control must be observed.
Barrier to coronavirus